Introduction {#Sec1}
============

Since 1954, a number of case reports have linked the use of high osmolality ionic iodine- based contrast media to the development of acute renal failure in patients with multiple myeloma (MM) and monoclonal gammopathies (MG) who had undergone excretory urography and/or, less frequently, retrograde pyelography, cholecystography or angiography \[[@CR1], [@CR2]\].

Concern about the use of iodine-based contrast medium in myeloma patients has been challenged since the 1980s, when it was suggested that the deterioration in renal function was due to dehydration, pre-existing renal failure, diabetes mellitus, hypercalcaemia and the use of nephrotoxic drugs, rather than to the iodine-based contrast medium \[[@CR3]\].

However, many radiologists and clinicians still consider MM and MG a contraindication to contrast medium use. They often require checks for Bence-Jones proteinuria before contrast-enhanced CT examinations, and deny clinically indicated investigations in myeloma patients. A survey among 2,000 practicing radiologists, members of the American College of Radiology (ACR), showed that 36 % of them never consider the use of iodine-based contrast media in myeloma patients \[[@CR4]\], and the ACR still considered MM a possible risk factor for post-contrast acute kidney injury as recently as 2016 \[[@CR5]\].

In view of these facts, the ESUR Contrast Media Safety Committee (CMSC) considered it necessary to undertake a systematic review of the available literature about the incidence of post-contrast acute kidney injury (PC-AKI) in patients with MM and MG, in order to produce evidence-based recommendations for the use of iodine-based contrast media in these patients. This study and the resulting guidelines were extensively discussed by the CMSC academic members and were also reviewed by the representatives of the pharmaceutical companies who are consultants to the Committee. A consensus report was agreed by the CMSC academic members at their meeting in February 2017.

Clinical features of monoclonal gammopathies {#Sec2}
--------------------------------------------

MG include a large spectrum of disorders characterised by proliferation of neoplastic plasma cells that synthesise an abnormal amount of monoclonal immunoglobulins or immunoglobulin fragments. The clinical manifestations and course of this group of disorders are heterogeneous ranging from benign gammopathies of undetermined significance (MGUS), which are stable for years and do not need any treatment, to aggressive myeloma with bone fractures, renal failure and impaired haemopoiesis at presentation and a poor response to any treatment.

Until 2014 MG were classified as MGUS, smouldering myeloma (SMM), symptomatic MM, solitary plasmacytoma and immunoglobulin light chain amyloidosis \[[@CR6]\]. MGUS and SMM are typically asymptomatic, and were differentiated by the level of the monoclonal protein and of clonal plasma cells in the bone marrow. The diagnosis of MM required demonstrable evidence of damage caused by the neoplastic plasma cells: hypercalcaemia, renal failure, anaemia and osteolytic bone lesions, commonly referred to as CRAB features. This definition ensured that patients with MGUS were not subjected to unnecessary chemotherapy, but in most patients with SMM, who have true malignancy, it is only a matter of time before end-organ damage occurs.

In recent years, reliable markers have been identified that can distinguish patients with SMM who are at imminent risk of end-organ damage. Also, improvements in myeloma treatment over the last 10 years suggest that therapeutic intervention at the SMM stage in these high-risk patients may improve quality of the life and overall survival. The main changes in the new classification \[[@CR7]\] include an updated definition of MM that includes not only CRAB but also: (1) bone marrow infiltration by clonal plasma cells of 60 % or greater; (2) a serum free-light chains (FLCs) involved/non-involved ratio of 100 or greater; (3) more than one focal bone or bone marrow lesion at least 5 mm in size at MRI. A creatinine clearance less than 40 ml/min is used as the cut off for renal failure. On the basis of this new classification, patients showing one or more of these abnormalities should be considered to have MM and should undergo specific treatment. Although an increased proportion of MM patients undergo treatment, there is a larger population of SMM with high levels of immunoglobulins having haematological follow-up without any treatment. In SMM and MM patients the high monoclonal FLCs can overwhelm the capacity of the proximal tubule to reabsorb them so that they reach the distal tubule where they interact with specific proteins generating myeloma casts. These casts may block glomerular flow causing tubular atrophy and interstitial fibrosis \[[@CR8]\]. Although the risk of renal failure increases with increasing concentrations of FLCs in the urine, this does not occur in all patients. In fact, not all monoclonal FLCs are equally nephrotoxic: the kidney injury depends partly on the type of FLCs and partly on environmental factors. At present, it is not possible to identify the potential nephrotoxicity of particular FLCs.

As well as the urine concentration of FLCs, there are many other factors that increase the risk of kidney damage in SMM and MM. These factors are in part secondary to MM, such as hypercalcaemia, hyperuricaemia, coexistent amyloidosis, hyperviscosity or abuse of non-steroidal anti-inflammatory drugs, and in part to comorbidity such as pre-existing nephropathy, diabetes mellitus, hypertension and cardiovascular disease. In a recent paper \[[@CR9]\], the prevalence of renal impairment in a large group of SMM (1,135 cases) was 20 % at presentation. However, the renal function of a large proportion of these patients (54 %) improved after anti-myeloma induction therapy. This indicates that renal damage is reversible with treatment and that reducing the FLCs is the most important factor in protecting renal function. The same study shows that if patients never recover their renal function, they have a very short overall survival and early mortality. The goal of treatment at any stage of the disease is to achieve the maximal possible response rapidly, with minimal toxicity, and to improve the patient's performance status.

Methods {#Sec3}
=======

For this systematic review, data collection and analysis were performed according to the guidelines of the PRISMA statement 2009 \[[@CR10]\]. Eligibility criteria and methods of analysis were specified in advance. Cohort studies and case-control studies reporting changes in renal function in patients with MM or MG following administration of iodine-based contrast media were included. Both non-controlled and controlled investigations, defined as studies in which patients with MM or MG were directly compared with patients without myeloma from the same community, were included. Studies in which a relationship between contrast medium administration and renal function changes could not be confirmed were excluded.

Search strategy {#Sec4}
---------------

A systematic search in Medline and Scopus databases was performed for studies of renal function deterioration in patients with MM or MG after administration of iodine-based contrast media. The search strategy was peer reviewed by an information specialist (DU). A combination of (MeSH) terms such as acute kidney injury, multiple myeloma, monoclonal gammopathies and synonyms was used. The complete Medline and Scopus search strategies are shown in Table [1](#Tab1){ref-type="table"}. The PubMed function 'Cited references' and reference lists of all included articles were screened for additional relevant literature. A database of retrieved articles was made using endnote X7.7.1 (Thomson Reuters), and all duplicates were removed.Table 1Search strategies**Database: PubMed (** [**http://www.ncbi.nlm.nih.gov/pubmed**](http://www.ncbi.nlm.nih.gov/pubmed) **)**DATE: no limits/last searched November 20 2016Total: 53Strategy:("Acute kidney injury"\[mesh\] OR "kidney diseases"\[mesh\] OR "acute kidney injury"\[tiab\] OR "renal function"\[tiab\] OR "nephropathy"\[tiab\] OR aki\[tiab\] OR "renal failure"\[tiab\] OR ARF\[tiab\] OR CIN\[tiab\]) AND ("contrast media"\[mesh\] OR "contrast media"\[tiab\] OR "contrast medium"\[tiab\] OR "contrast induced"\[tiab\]) AND (multiple myeloma\[mesh\] OR "myeloma"\[tiab\] OR "monoclonal gammopathies"\[tiab\])**Database: Scopus (** [**http://www.scopus.com**](http://www.scopus.com) **)**DATE: no limits/last searched November 20 2016Total: 116 (26 excluding PubMed duplicates)Strategy:TITLE-ABS-KEY ("Acute kidney injury" OR "kidney diseases" OR "renal function" OR "nephropathy" OR "aki" OR "renal failure" OR "ARF" OR "CIN") AND TITLE-ABS-KEY ("contrast media" OR "contrast medium" OR "contrast induced") AND TITLE-ABS-KEY ("myeloma" OR "monoclonal gammopathies")

Selection of studies {#Sec5}
--------------------

The first selection was made independently by two reviewers (FS and MB) with 34 and 21 years of experience in diagnostic imaging, respectively. Selection was based on the title and abstract without blinding to the authorship or journal. Then, references in full text that were deemed potentially relevant by either or both of the reviewers were retrieved, and evaluated according to their eligibility criteria. Non-English language articles were reviewed by native-language speakers to determine eligibility. No restrictions were imposed in relation to study design. If eligibility was doubtful, articles were discussed by the reviewers and were included or excluded based on consensus.

Data extraction and data analysis {#Sec6}
---------------------------------

Information from each reference was extracted by two reviewers (FS and MB) working independently. The studies were categorised based on (1) type (systematic review, review article, case report, cohort or case-control studies); (2) number of contrast studies and of patients investigated (both myeloma patients and control patients from the same population, when present); (3) type of iodine-based contrast medium and route of administration; (4) possible causes for renal function deterioration other than iodine-based contrast medium administration; and (5) number of unconfounded associations between contrast administration and renal function deterioration. Unconfounded cases of contrast induced acute kidney injury (CI-AKI) were defined as situations in which post-contrast acute kidney injury (PC-AKI) could not be explained by comorbidity or causes other than contrast medium administration. The reviewers then graded the methodological quality of cohort and case-control studies by using the Newcastle-Ottawa scale for non-randomised studies \[[@CR11]\]. Discrepancies were resolved by consensus.

Finally, based on the literature and the CMSC consensus, each guideline was graded using the Oxford Centre for Evidence Based Medicine (OCEBM) 2011 evidence classification: Grade A: established scientific evidence, Grade B: scientific presumption, Grade C: low level of evidence \[[@CR12]\]. Recommendations based on CMSC consensus only were given Grade D because they were based on expert opinion.

Results {#Sec7}
=======

The search and selection procedures used are shown in Fig. [1](#Fig1){ref-type="fig"}. Most studies were excluded during title and abstract review because they were not relevant to the clinical problem being studied. A total of 55 publications were considered potentially relevant and were retrieved in full text. Of these, 41 were excluded for a variety of reasons: 14 were case reports, 12 were review articles, two were in vitro studies in which no patients were investigated and nine were surveys, letters, consensus documents or editorials. In three studies the number of patients having iodine-based contrast medium or MM was not reported. The last paper was not about myeloma.Fig. 1Search and selection procedures

This left 14 observational studies that met the eligibility criteria used for this review \[[@CR2], [@CR13]--[@CR25]\] (Table [2](#Tab2){ref-type="table"}); 11 were retrospective and three were prospective \[[@CR16], [@CR21], [@CR25]\]. Thirteen were cohort studies and one was a case-control study \[[@CR25]\]. The Newcastle-Ottawa scores indicated quality levels ranging between 5 and 9 on a scale of grades 0--9 for cohort studies and 0--8 for case-control studies, except for one investigation \[[@CR17]\] with a score of 1 (Table [3](#Tab3){ref-type="table"}). This last study reported anecdotally on 18 intravenous urograms in 16 myeloma patients in whom no complications were observed and it was excluded from the systematic review. This left 13 studies with average Newcastle-Ottawa score grade 6.2 for evaluation. Of these, eight studies in which there was either no control group or the control group could not be evaluated \[[@CR18]\] had lower scores of 5--6.Table 2Characteristics of included studiesStudy, yearStudy designNo. of exams/patientsTechniqueContrast medium typePathologyCIN (unconfounded)Brown et al. 1964 \[[@CR15]\]Retrospective39/46U, 43\
RP, 3Iodopyracet,3\
Sodium Acetrizoate, 1Myeloma4 \*Lasser et al. 1966 \[[@CR17]\]Retrospective18/16UUnknownMyeloma0Morgan et al. 1966 \[[@CR18]\]Retrospective\
Retrospective19/18\
105/105U\
UUnknown\
UnknownMyeloma0 \#\
0 \#Vix et al. 1966 \[[@CR22]\]Retrospective52/40UUnknownMyeloma0Svoboda et al. 1967 \[[@CR24]\]Retrospective13/13\
2/2U\
CIodopyracet §\
Acetrizoate §\
Diatrizoate §\
Variety of contrast media §Myeloma0Fateh-Moghadam 1969 \[[@CR23]\]Retrospective55/69U, 66\
RP, 3Diatrizoate (probably)Monoclonal gammapathies0¶Myers et al. 1971 \[[@CR19]\]Retrospective236/201U, 218\
U+RP, 18DiatrizoateMyeloma0†Defronzo et al. 1975 \[[@CR2]\]Retrospective4/4UUnknownMyeloma1Ansari et al. 1976 \[[@CR13]\]Retrospective1\*\*UDiatrizoateMyeloma0 ßBaltzer et al. 1978 \[[@CR14]\]Retrospective41/31UDiatrizoate, 28 ¥\
Iothalamate meglumine, 14 ¥Myeloma0Gassmann et al. 1983 \[[@CR16]\]Prospective34/26UIothalamate meglumineMyeloma0Uchida et al. 1995 \[[@CR21]\]Prospective13/10U, 5\
Unknown 8UnknownMyeloma3Pahade et al. 2011 \[[@CR20]\]Retrospective80/46CECTIodixanol, 10\
Ioversol, 70Myeloma4Preda et al. 2011 \[[@CR25]\]Prospective130/30CECTIodixanolMonoclonal gammapathies0\*All patients had severe proteinuria. Three, possibly all, had renal failure before urographic examination. Two developed urinary tract infection after retrograde pyelography\# Two independent patient series from two different hospitals§ Iodine-based contrast administered to the single patients unknown¶ Three confounded cases in patients with multiple comorbidities, dehydration and renal failure† One confounded case in a patient with pre-existing renal failure who developed ARFß 25 patients with CIN. One patient with confounded CIN had myeloma. CIN is confounded in this patient because the patient had fluid deprivation the night before the examination, and septicaemia, and it is not clear whether this was already present at the time of urography¥ Number of patients extrapolated from reported percentages*CECT* contrast-enhanced CT, *U* urography, *RP* retrograde pyelography, *ARF* acute renal failure, *C* cholangiography Table 3Quality of studiesStudyStudy designAverage Newcastle-Ottawa scoreBrown et al. 1964 \[[@CR15]\]Retrospective cohort5Lasser et al. 1966 \[[@CR17]\]Retrospective cohort1Morgan et al. 1966 \[[@CR18]\]Retrospective cohort6Vix et al. 1966 \[[@CR22]\]Retrospective cohort8Svoboda et al. 1967 \[[@CR24]\]Retrospective cohort5Fateh-Moghadam 1969 \[[@CR23]\]Retrospective cohort5Myers et al. 1971 \[[@CR19]\]Retrospective cohort7Defronzo et al. 1975 \[[@CR2]\]Retrospective cohort5Ansari et al. 1976 \[[@CR13]\]Retrospective cohort5Baltzer et al. 1978 \[[@CR14]\]Retrospective cohort9Gassmann et al. 1983 \[[@CR16]\]Prospective cohort5Uchida et al. 1995 \[[@CR21]\]Prospective cohort8Pahade et al. 2011 \[[@CR20]\]Retrospective cohort5Preda et al. 2011 \[[@CR25]\]Prospective case-control8

The 13 selected studies were markedly heterogeneous both in relation to type of investigation and contrast medium (Table [2](#Tab2){ref-type="table"}). They report a total of 824 iodine-based contrast medium administrations in 642 patients with MM (639 administrations in 543 patients) or MG (185 administrations in 99 patients), in which 12 unconfounded cases of post contrast acute kidney injury were found (1.6 %). In 11 of the studies high osmolality ionic contrast media were used. Low osmolality non-ionic contrast media were used in two studies in which contrast-enhanced CT was performed 210 times in 76 patients with myeloma (n=46) or gammopathies (n=30) \[[@CR20], [@CR25]\]. PC-AKI was observed in 4/210 (1.9 %) cases \[[@CR20]\]. These four patients had normal creatinine levels ranging from 0.9 to 1.3 mg/dl before contrast medium administration, and these increased slightly within 48 h after contrast injection (range: 1.2--1.6 mg/dl).

Discussion {#Sec8}
==========

Contrast-enhanced studies with iodine-based contrast media are not routinely performed to stage MM or to investigate MG, but may be required to detect complications of the disease. However, many radiologists withhold iodine-based contrast media from all patients with MM or MG because they are considered at very high risk of acute kidney injury \[[@CR4]\]. Until 2016, the ACR Manual on Contrast Media (version 10.2) stated that "paraproteinaemias, particularly MM, are known to predispose patients to irreversible renal failure after high osmolality contrast media administration due to tubular protein precipitation and aggregation; however, there is no data predicting risk with the use of low osmolality or iso-osmolality agents" \[[@CR5]\]. This statement no longer appears in the 2017 ACR Manual (Version 10.3) \[[@CR26]\]. As early as 1992 McCarthy and Becker \[[@CR27]\] reviewed the literature on renal failure after high osmolality contrast media, and stated that major risk factors for acute renal failure in myeloma patients were not intravenous contrast media as once suspected, but rather hypercalcaemia, dehydration, infection and Bence-Jones proteinuria. They also noted that it was uncertain whether high osmolality contrast further increases these risks and that some of the older contrast media precipitate Bence-Jones protein in vitro.

Our review showed that the literature available is both limited and heterogeneous. There are a number of case reports. De Fronzo et al. \[[@CR2]\] in 1975 collected 29 published case reports of acute renal failure in patients with MM who underwent intravenous urography (16 apparently with baseline normal renal function and 13 with chronic renal insufficiency). No randomised and very few controlled trials are available, and most studies are retrospective. Many studies were published before 1980. Most of the myeloma patients had intravenous urography after preparatory dehydration and purgation and ionic high osmolar contrast media that have been withdrawn from the market in most countries were used. Also, a variety of imaging techniques were used and there were no studies using intra-arterial contrast injection. Furthermore, different criteria for detecting post-contrast renal function deterioration were used. Only two studies considered the use of the non-ionic contrast media that are in wide use currently in patients with MM and MG. All these features limit the value of our systematic review.

The recent retrospective study by Pahade et al. \[[@CR20]\] showed that the incidence of AKI following non-ionic contrast medium administration (ioversol or iodixanol) in patients with MM with a normal SCr is low and correlates with β~2~-microglobulin levels (which increase both with higher tumour burden and diminished renal function). Additionally, Preda et al. \[[@CR25]\] carried out a prospective study showing that the use of a non-ionic dimer (iodixanol) is safe in patients with MG and an eGFR ≥60 ml/min/1.73 m^2^.

Although the evidence provided by the literature is rather poor, it appears that MM and MG alone cannot be considered a risk factor for AKI following intravenous iodine-based contrast medium administration. However, the risk may become significant when SMM and MM are associated with impaired renal function \[[@CR8]\]. It therefore appears that, in cases of SMM or MM with normal renal function, it is not necessary to measure the urinary light chains before iodine-based contrast administration. In fact, if renal function is preserved, urinary light chains are unable to cause renal damage whatever their concentration. Therefore, in patients with normal renal function there is no need to check for Bence-Jones proteinuria, since this test cannot be considered as a surrogate biomarker of kidney function \[[@CR8], [@CR20]\]. When there is renal impairment, the usual rules for preventing PC-AKI should be considered, such as the possibility of an alternative imaging method not using iodine-based contrast media and volume expansion \[[@CR28]\]. If contrast media are required for clinical reasons in patients with SMM or MM, measuring the serum calcium is much more important than checking the urinary FLCs. High concentrations of serum calcium are relatively common in any stage of SMM or MM, and are an important risk factor for AKI. Hypercalcaemia induces vasoconstriction and can inhibit antidiuretic hormone activity, so causing dehydration, which further increases the risk of myeloma casts, leading to worsening of the renal impairment \[[@CR8]\]. Haematologists are fully aware of the risk of hypercalcaemia in SMM and MM, and serum calcium measurement is now one of the tests routinely performed in the follow-up of all stages of the disease. Also, hypercalcaemia is usually symptomatic causing malaise, constipation, anorexia, nausea, lethargy, confusion, coma and cardiovascular manifestations such as shortening of the QT interval and dysrhythmias. Therefore, it is very unlikely that an imaging method requiring iodine-based contrast medium administration will be requested without knowledge of the patient's serum calcium. The treatment of hypercalcaemia is usually easy and includes aggressive re-hydration followed by diuresis with frusemide, which increases urinary calcium excretion, and intravenous bisphosphonate (pamidronate or zoledronic acid).

Conclusion {#Sec9}
==========

Modern non-ionic iodine-based contrast media can safely be administered to patients with MM or MG who have normal renal function. However, comorbidity, such as impaired renal function and hypercalcaemia, which increases the risk of AKI, frequently coexists in these patients and close cooperation between radiologists and referring clinicians is needed for optimal management of these patients. Simple guidelines are proposed (Table [4](#Tab4){ref-type="table"}).Table 4Multiple myeloma and monoclonal gammopathy patients: ESUR CMSC guidelinesLevel of evidence (\*)• Multiple myeloma and monoclonal gammopathy patients with normal renal function are not at increased risk of PC-AKI provided that they are well hydrated and that low- or iso-osmolar iodine-based contrast media are usedB• Multiple myeloma patients often have reduced renal function, and such patients are at increased risk of PC-AKIA• Multiple myeloma patients often have hypercalcaemia which can increase the risk of kidney damage. Correction of hypercalcaemia before contrast medium administration should be discussed with the haematologistD• Assessment for Bence Jones proteinuria before contrast medium administration is not necessaryA\*Level of Evidence is graded using the Oxford Centre for Evidence Based Medicine (OCEBM) 2011 classification: Grade A: established scientific evidence, Grade B: scientific presumption, Grade C: low level of evidence. Recommendations based on CMSC consensus only were given Grade D (expert opinion)*PC-AKI* post-contrast acute kidney injury
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